A Secret Weapon For "3
All enrolled sufferers who gained at the least one dose of zosuquidar or placebo for the duration of induction were monitored for your event of adverse situations (439 patients, 219 on zosuquidar and 210 on placebo). The most common adverse functions ended up related to the duration of extended and substantial myelosuppression as is anticipated wit